Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
CARA's Cash-to-Debt is ranked higher than
75% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. CARA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CARA' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.43  Med: No Debt Max: No Debt
Current: No Debt
1.43
No Debt
Interest Coverage No Debt
CARA's Interest Coverage is ranked higher than
68% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CARA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CARA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 35.26
Beneish M-Score: -4.31
WACC vs ROIC
23.10%
1181.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -5958.73
CARA's Operating Margin % is ranked lower than
91% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. CARA: -5958.73 )
Ranked among companies with meaningful Operating Margin % only.
CARA' s Operating Margin % Range Over the Past 10 Years
Min: -67906.98  Med: -615.58 Max: -1.98
Current: -5958.73
-67906.98
-1.98
Net Margin % -5783.53
CARA's Net Margin % is ranked lower than
91% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. CARA: -5783.53 )
Ranked among companies with meaningful Net Margin % only.
CARA' s Net Margin % Range Over the Past 10 Years
Min: -66604.65  Med: -603.89 Max: -33.12
Current: -5783.53
-66604.65
-33.12
ROE % -66.45
CARA's ROE % is ranked lower than
72% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. CARA: -66.45 )
Ranked among companies with meaningful ROE % only.
CARA' s ROE % Range Over the Past 10 Years
Min: -84.54  Med: -73.54 Max: -31.51
Current: -66.45
-84.54
-31.51
ROA % -58.94
CARA's ROA % is ranked lower than
77% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. CARA: -58.94 )
Ranked among companies with meaningful ROA % only.
CARA' s ROA % Range Over the Past 10 Years
Min: -91.77  Med: -65.57 Max: -29.6
Current: -58.94
-91.77
-29.6
ROC (Joel Greenblatt) % -4221.15
CARA's ROC (Joel Greenblatt) % is ranked lower than
80% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. CARA: -4221.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CARA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4262.63  Med: -736.13 Max: -7.37
Current: -4221.15
-4262.63
-7.37
3-Year Revenue Growth Rate -42.40
CARA's 3-Year Revenue Growth Rate is ranked lower than
91% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CARA: -42.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CARA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -62.4 Max: -8.3
Current: -42.4
3-Year EBITDA Growth Rate -31.80
CARA's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CARA: -31.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CARA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -15.9 Max: -4.1
Current: -31.8
3-Year EPS without NRI Growth Rate -29.80
CARA's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CARA: -29.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CARA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.9 Max: 1.6
Current: -29.8
0
1.6
GuruFocus has detected 4 Warning Signs with Cara Therapeutics Inc CARA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CARA's 30-Y Financials

Financials (Next Earnings Date: 2018-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

CARA Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q1 2017

CARA Guru Trades in Q1 2017

Paul Tudor Jones 73,635 sh (New)
Steven Cohen 50,000 sh (unchged)
» More
Q2 2017

CARA Guru Trades in Q2 2017

Joel Greenblatt 29,081 sh (New)
Steven Cohen 25,000 sh (New)
Steven Cohen 25,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q3 2017

CARA Guru Trades in Q3 2017

Steven Cohen Sold Out
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CARA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Sold Out 0.01%$12.21 - $16.43 $ 16.8621%0
Joel Greenblatt 2017-06-30 New Buy0.01%$14.5 - $26.95 $ 16.86-5%29,081
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Cara Therapeutics Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:SZSE:002868, WAR:CLN, XPAR:IPH, XSWX:SKIN, NAS:IDRA, NAS:ADVM, XTER:MDG1, NAS:NITE, NAS:SYRS, LSE:ARIX, NAS:PIRS, SHSE:603229, NAS:MRSN, TSXV:EMH, LSE:CIR, NAS:SNNA, NAS:CORI, OTCPK:RCAR, OSTO:ONCO, XKRX:019175 » details
Traded in other countries:69C.Germany,
Headquarter Location:USA
Cara Therapeutics Inc is an emerging biotechnology company. It is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.

Cara Therapeutics is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Top Ranked Articles about Cara Therapeutics Inc

Factors of Influence in 2018, Key Indicators and Opportunity within Camden National, Cara Therapeutics, Albany International, Emerge Energy Services LP, Fiesta Restaurant Group, and Resources Connection — New Research Emphasizes Economic Growth
Cara Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
Thinking about buying stock in Cara Therapeutics, Lowes, Neovasc Inc., Tiffany & Company or Target?
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus
Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting 
Cara Therapeutics Reports First Quarter 2018 Financial Results
Cara Therapeutics to Announce First Quarter 2018 Financial Results on May 9, 2018
Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of Oral KORSUVA™
Cara Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference

Ratios

vs
industry
vs
history
PB Ratio 7.66
CARA's PB Ratio is ranked lower than
52% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CARA: 7.66 )
Ranked among companies with meaningful PB Ratio only.
CARA' s PB Ratio Range Over the Past 10 Years
Min: 1.23  Med: 4.61 Max: 17.15
Current: 7.66
1.23
17.15
EV-to-EBIT -9.21
CARA's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. CARA: -9.21 )
Ranked among companies with meaningful EV-to-EBIT only.
CARA' s EV-to-EBIT Range Over the Past 10 Years
Min: -114.5  Med: -6.45 Max: -0.9
Current: -9.21
-114.5
-0.9
EV-to-EBITDA -9.29
CARA's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. CARA: -9.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
CARA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -180.9  Med: -6.5 Max: -0.9
Current: -9.29
-180.9
-0.9
EV-to-Revenue 547.37
CARA's EV-to-Revenue is ranked lower than
88% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. CARA: 547.37 )
Ranked among companies with meaningful EV-to-Revenue only.
CARA' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.1  Med: 79.75 Max: 4606
Current: 547.37
6.1
4606
Current Ratio 11.46
CARA's Current Ratio is ranked higher than
90% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. CARA: 11.46 )
Ranked among companies with meaningful Current Ratio only.
CARA' s Current Ratio Range Over the Past 10 Years
Min: 0.73  Med: 11.46 Max: 34.29
Current: 11.46
0.73
34.29
Quick Ratio 11.46
CARA's Quick Ratio is ranked higher than
90% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. CARA: 11.46 )
Ranked among companies with meaningful Quick Ratio only.
CARA' s Quick Ratio Range Over the Past 10 Years
Min: 0.73  Med: 11.46 Max: 34.29
Current: 11.46
0.73
34.29
Days Sales Outstanding 49.28
CARA's Days Sales Outstanding is ranked lower than
96% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. CARA: 49.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
CARA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.68  Med: 49.28 Max: 369.24
Current: 49.28
7.68
369.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.70
CARA's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CARA: -12.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CARA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -66.1  Med: -10.2 Max: 0
Current: -12.7
-66.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.35
CARA's Price-to-Net-Cash is ranked higher than
68% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. CARA: 8.35 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CARA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.74  Med: 4.84 Max: 22.16
Current: 8.35
1.74
22.16
Price-to-Net-Current-Asset-Value 7.84
CARA's Price-to-Net-Current-Asset-Value is ranked higher than
67% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. CARA: 7.84 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CARA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.65  Med: 4.68 Max: 18.58
Current: 7.84
1.65
18.58
Price-to-Tangible-Book 7.63
CARA's Price-to-Tangible-Book is ranked higher than
57% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CARA: 7.63 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CARA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.59  Med: 4.59 Max: 17.15
Current: 7.63
1.59
17.15
Earnings Yield (Greenblatt) % -10.88
CARA's Earnings Yield (Greenblatt) % is ranked lower than
70% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. CARA: -10.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CARA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -109.2  Med: -15.5 Max: -0.9
Current: -10.88
-109.2
-0.9

More Statistics

Revenue (TTM) (Mil) $0.91
EPS (TTM) $ -1.61
Beta3.36
Volatility39.99%
52-Week Range $11.11 - 28.50
Shares Outstanding (Mil)33.87

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 18 4 23
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.57 -2.27 -2.39
EPS without NRI ($) -1.57 -2.27 -2.39
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}